Company intelligence / Profile preview

Verex Laboratories

Englewood, Colorado, USA

Ownership: Private
Development stage: Other

Overview

Verex Laboratories was a specialty pharmaceutical company focused on the development of innovative drug delivery systems, particularly oral transmucosal technologies. The company's primary expertise lay in creating formulations for rapid drug absorption through the buccal and sublingual mucosa. Its most notable development efforts were centered around fentanyl-based products for the treatment of breakthrough cancer pain. In 2007, the company was acquired by Mylan Laboratories to bolster Mylan's branded and specialty product portfolio.

Therapeutic areas: OncologyNeurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Mylan

Beyond the preview

Go deeper on Verex Laboratories.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Verex Laboratories.

Explore the full profile